Hi {{ session.user.profile.firstName }}

Medical Research

  • Pieter will be speaking about his Number 1 Neurosurgical app in the world, "Neuromind", as well as other web developments in the medical field, including his work in the IT department of his hospital, as well as his passion for Medical Infomatics
  • Cerepro is an app designed for patients with Traumatic Brain Injury, by a patient who, himself, suffered this type of injury. He discusses the purpose of this app to rehabilitlate Traumatic Brain Injury Patients in both their focal motor, and memory skills.
  • John Rogers PhD of the Nicholson Training center in Orlando, Florida is interviewed about this Robotics Surgical Training center outlining the features as discussing the future of Surgical Robotics Surgery
  • Richard Mendel MD, a Spinal Neurosurgeon from Tampa, Florida, gives a presentaion on the Basics of Stem Cells. Stem Cell Treatments are becoming more popular, and it benefit all to know the basics of this growing science.
  • Shahriar Yaghoubi PhD MBA Interview speaking about the status of Cancer Immunotherapy, and the future of this dynamic field
  • Th​is webinar will provide an overview on the topic of analyzing various fatty species in foods and methods to determine various classes from total fat to various lipid fractions and the wide variety of analyses available for fat determination. Topics discussed will include the analyses of fatty acid methyl esters (FAMES) in foods and the use of comprehensive two-dimensional gas chromatography (GC x GC) for the enhanced separation of highly complex mixtures. Advances in GC column stationary phases and new phases based on ionic liquid technology for the analyses of saturated and polyunsaturated FAMES will be discussed aswell as the use of GC×GC in the field of food lipid analysis. The considerable advantages of the two-dimensional approach (both with and without MS detection), in experiments related to a series of lipid volatiles (fatty acids, sterols, oxidation products, fatty alcohols, etc) will be illustrated.

    In this webinar, we will:

    > Overview the wide variety of methods available for the analysis of fat in foods.

    > Examine traditional and new classes of GC Stationary Phases for the evaluation of various FAME species.

    > Discuss the power of two-dimensional gas chromatography (GCxGC) for separating highly complex mixtures and how it can be combined with mass spectrometry for analyzing volatile and semi-volatile analytes
  • As developments in quantum computing accelerate and the potential to increase the capabilities of tomorrows computers becomes a reality, leading research scientists discuss their research at key international establishments.

    “Enabling processes and tools for research and fabrication of Qubits”, Dr David Haynes, Oxford Instruments

    “A valley-spin qubit in a carbon nanotube”,
    Dr Edward Laird, Materials Department, Oxford University

    “Next-generation cQED processors”,
    Dr. Alessandro Bruno, post-doc researcher, Quantum Computing Lab (QcLab), Kavli Institute of Nanoscience and QuTech, Delft University of Technology
  • Digital – a word which is ubiquitous within our industry now and no longer the exclusive domain of IT or marketing. It should not be seen as simply an enabler; intelligent and progressive digitisation is now a fundamental business need in all areas of pharma and healthcare.

    We present an exclusive webinar with global data centre and interconnectivity specialist Equinix, joined by digital and technology experts FFW and moderated by our own Paul Tunnah. This debate will provide practical insight and delve deep into the challenges at hand in managing the digitisation of our industry.

    Topics covered will include:
    •Why being digital is no longer an IT function but rather a business need – analysis and insight into the current market and the coming 3 to 5 years
    •Managing data – how pharma needs to change its IT foundations to remain commercially optimised in a changing healthcare environment, including the move from pill to patient
    •How industry can prepare – why connected is not enough – definition and benefits of interconnectivity, with learnings from the financial sector
  • Objectives:
    (1) Review the unique nutritional needs of preterm infants (2) Review the incidence and causes of extrauterine growth restriction (EUGR) in VLBW infants (3) Summarize the evidence regarding the impact of nutrition on neurodevelopmental outcomes (4) Define the protein and energy requirements of VLBW infants (5) Discuss a variety of nutritional strategies for meeting protein and energy requirements of VLBW infants
  • Because of worldwide demographic changes a dramatic increase of the geriatric population is expected in the next decades. While pediatric drug delivery principles are becoming integrated into the development of new medicines, drug developers are less prepared to appropriately address the specific needs of this booming patient population. This webinar tries to give an overview about the possible drug delivery strategies addressing old age dependent differences. There will be specifically focused on how patient convenience and compliance can be improved, how disease specific drug delivery strategies can help geriatric patients, and how learnings from pediatric drug development can be used as a platform towards geriatric drug delivery.
  • What you’ll learn about the AU5800 chemistry analyzer:

    •Typical performance observed (reproducibility, reference ranges)
    •Impact on the laboratory’s turnaround time (TAT) targets
    •Operator feedback on instrument features
    •Instrument uptime metrics

    P.A.C.E. credit will be available for your participation*
  • Chemical probes are powerful reagents with increasing impacts on biomedical research. However, probes of poor quality or that are used incorrectly generate misleading results. To help address these shortcomings, we are building a community-driven online resource to improve quality and convey current best practice.
    In this presentation, we will highlight some selected examples of promising, high quality chemical probes and probes of lesser value. We will discuss the prevalence of using lesser quality probes and the costs. We will then detail our plans to develop the Chemical Probes Portal, a web-based resource annotated by the chemical biology community that allows users to reference the most appropriate chemical probe (or probes) for a given protein target. The Portal will be an online community of scientists, reviewers, editors.
  • The importance of genetic variations in drug transporters for drug disposition and response has been increasingly recognized in the past decade. The drug transporter organic anion transporting polypeptide 1B1 (OATP1B1) is genetically polymorphic and plays a major role in hepatic uptake of a variety of clinically important drugs. Predicting the pharmacokinetic effect of these genetic variants on the drug disposition is critical for understanding the inter-individual variations to drug efficacy and safety. Corning TransportoCells was introduced to support in vitro assessment of drug interaction with SLC transporter. Specially, the newly developed TransportoCells OATP1B1 SNPs, alongside with OATP1B1 wild type, offer an in vitro tool kit for studying the potential impact of genetic variants on drug PK.

    This webinar will focus on the development and characterization of the newly available TransportoCells OATP1B1 genetic variants, three animal species Oatp family members and other drug transporters of emerging importance in drug development.
  • NIR has proven to be a fast, flexible, and reliable method along the pet food value chain; from incoming raw material inspection to in-process and final product testing, see how BUCHI NIRSolutions® can be used to increase plant efficiency, product quality, and profit margins.
    During this webinar, you will:
    • Gain an understanding of basic NIR theory and the reasons this technology has been implemented by pet food manufacturers
    • See how fast, qualitative NIR methods can ensure consistent quality of in-coming raw materials
    • Learn how to utilize quantitative NIR measurements, from raw material analysis to finished pet food product
    • Get introduced to our portfolio of NIRSolutions and learn how to integrate these technologies for ultimate process and quality control
  • Reproducibility is one of the pillars of the entire scientific method, a benchmark upon which the reliability of one’s research can be tested. Yet many authors struggle with the proper reporting of their statistical methods, leading to revision and often rejection. Our team of experts will provide recommendations, best practices, and real-life examples for presenting research that is transparent, robust, and most importantly, reproducible.

    Speakers and topics will include:

    • William Irish, PhD, MSc, Vice President, CTI Clinical Trial and Consulting Services, Raleigh, NC
    “Reporting of Statistical Methods and Results: Importance of Good Communication”
    • Dana Turner, Design and Methods Advisor, Headache: The Journal of Head and Face Pain
    “Best Practices for Reporting Methods and Statistics & Ways to Avoid Common Pitfalls”
    • Benjamin Hofner, Reproducible Research Editor, Biometrical Journal; FAU Erlangen-Nürnberg
    “Reproducible Research - A Review and Recommendations”
    • William G. Jacoby, Editor, American Journal of Political Science; Professor, Michigan State University
    “The Replication Policy at the American Journal of Political Science: Experiences during the First Six Months”
  • Drug target validation is a major obstacle to drug development leading to high rates of late-stage failure because the pivotal study in drug development - the randomised trial – occurs at the end of the development pipeline.

    Genetic studies using the principle of Mendelian randomisation reproduce key elements of a randomised trial ensuring target validation can take place earlier in development.

    A second major obstacle in drug development is the understanding of individual differences in drug efficacy and safety due to naturally occurring variation in gene encoding proteins involved in drug disposition – a key component of stratified medicines research.

    The Illumina Drug Development Array is designed to address issues and enable genomic discoveries to be used in drug development.

    The array combines the genome-wide tag SNP content of the Illumina Human Core BeadChip (240,000 highly-informative genome-wide tag SNPs and over 20,000 high-value markers) with a novel 200,000 custom marker set designed to support studies of drug target validation and treatment response. The array is relevant to full range of human drug targets and medical disorders.

    The webinar will:

    - Introduce the concept of Mendelian randomisation studies for target selection and validation in drug development

    - Discuss the concept of the ‘druggability’ and the ‘druggable genome’

    - Describe development of the content of the Illumina drug development array based on an updated set of genes encoding druggable targets and the proteins involved in in drug absorption, distribution, metabolism and excretion (ADME)


    - Prof. Aroon Hingorani, Chair of Genetic Epidemiology, Institute of Cardiovascular Science, University College London

    - Prof. John Overington, Visiting Professor of Computational Chemical Biology, Institute of Cardiovascular Science, University College London

    - Dr. Anna Gaulton, Senior Data Integration and Development Officer – ChEMBL, European Bioinformatics Institute, Hinxton
  • Direct Oral Anticoagulants (DOACs) have become widely prescribed. Clinical indications of DOACs include stroke prevention in non-valvular atrial fibrillation, thromboprophylaxis following hip or knee replacement surgery, and treatment or prevention of venous thromboembolic disease, among others.

    Although DOACs do not require routine monitoring, there are instances when determining DOAC concentration in the blood can be useful in ensuring optimal patient care.

    In this ILluminations Webinar, Dr. Tripodi will describe the primary characteristics of both “new” and “old” anticoagulant drugs, with a focus on the benefits of measuring DOAC concentration in certain clinical scenarios. He will elaborate on how to test for commercially available DOACs (e.g., dabigatran, rivaroxaban and apixaban), the alerting value ranges for DOAC concentrations, and how DOACs affect the most common hemostatic parameters.
  • Shahriar Yaghoubi PhD, a leading genetic researcher who works with Cell Sight Technologies is interviewed about various topics including Cancer Immunotherapy and his company, www.cellsighttech.com
  • The Particle Tracing Module extends the functionality of the COMSOL Multiphysics modelling environment, to allow the computation of the trajectories of particles in fluids and charged particles electromagnetic fields. The particles can be subjected to a wide variety of forces, such as electrical, drag, and thermophoretic forces, as well as particle-particle and fluid-particle interactions. This webinar introduces particle tracing for applications such as erosion, etching, mixing, filtration, mass spectrometry, ion optics, and beam physics. The webinar includes a demonstration and will end with a Q&A session.

    Edmund studied chemistry at the University of Oxford from 2004 to 2008. He then continued on for a doctorate at Oxford, researching the charge and mass transfer properties of electrolyte solutions. He joined COMSOL as an application engineer, where he specialises in chemistry, heat transfer and fluid flow.
  • Policies in ASEAN are directed towards creating a single ASEAN market. It will be achieved through individual national initiatives to increase the competitiveness of their nation, providing a single window to access an estimated 671.6 million consumers with a combined estimated GDP per capita of $6,552 in 2020.

    The study of the TOP 6 policies in ASEAN reveals their impact towards healthcare delivery value chain from manufacturer and suppliers to the hospitals and insurers, and where opportunities for growth, diversification and change of business models are expected.

    Expected tangible insights:-
    •ASEAN Healthcare Market – Size and Projected Growth
    •Stages of development and compliances to policies
    •Insights and analysis of the following:-
    oASEAN Economic Community
    oASEAN Medical Device Directive
    oUniversal Health Coverage in Indonesia
    oOnline-Catalogue and Purchasing
    oThailand Medical Hub
    oMyanmar Companies Act
    •Market Opportunities and Risks
    •Game Changing Environments
  • This 30 minute webinar will describe the design and application of pooled CRISPR libraries. A Sigma-Aldrich technology expert will discuss unique features of Sigma CRISPR pooled libraries with special attention to CRISPR design and cell culture needs.
  • Are you ready for Telehealth and Integrated Care management? Imagine a world where an injured athlete has access to a specialist while still on the field. A world in which specialists interact with patients while they are at home. A world in which patients have instant access to specialists and doctors when need arise. Dell can help you with Real-time access to quality care, lower cost of providing care and better management of reimbursement risk. We integrate video based and remote monitoring platforms to better connect patients and providers instantly. With use can reduce rebound rates, cut costs, improve clinical outcomes and improve your customers healthcare experience.
  • - Hear examples of unstructured data types most commonly added to healthcare Big Data implementations
    - From the semantic web to ICU audio files, which are the most interesting data sources inside and outside of the clinic
    - The coolest ‘v’ of the four ‘v’s of Big Data is variety; hear best practices on adding this to a data lake
    - Predicting readmission and sepsis has proliferated, what’s next?
    - Data science is now mainstream and much easier in a Big Data sandbox, what’s the easiest way to set this up in healthcare?
  • G-protein coupled receptors (GPCRs) are the primary target class of currently marketed drugs, accounting for around a third of all drug targets of approved medicines. However, almost all the screening efforts for novel ligand discovery rely exclusively on cellular systems overexpressing the receptors. Current receptor assay systems are based on measurement of either ligand displacement or downstream functional responses, rather than direct observation of ligand binding. Issues of allosteric modulation, probe dependence and functional selectivity create challenges in selecting suitable assays formats. Therefore a method that directly measures GPCR-ligand interactions, independent of binding site, probe and signalling pathway would be a useful primary and orthogonal screening method. An alternative ligand discovery strategy would be the direct measurement of GPCR-ligand interactions by label-free technologies, such as surface plasmon resonance (SPR). However label-free biophysical screening methods have not been routinely applied to membrane proteins. Current developments are looking at improving GPCR biosensor assays for SPR instruments and applying these to a range of drug discovery and biological functions, including kinetic analysis, allosteric discovery, fragment screening and functional selectivity. Biosensor-based direct screening methods enable the identification of the interaction of both orthosteric and allosteric ligands with solubilised, wild type GPCRs, in a label-free and cell-free environment, thus overcoming the limitations of indirect and displacement assay methods.
  • Peter will share experiences and observations how the scientific high-tech community, can benefit from adopting paperless processes in the laboratory. Is it because paper doesn’t require any significant investment budget, or is it the low barrier to access, since paper even works without power or the need to have access to an information infrastructure, or is it just simply that the “what’s in it for me” question hasn’t been answered satisfactorily for the scientists?
    Cross-functional collaboration between research, development, quality assurance and manufacturing is all about optimising and integrating multi-discipline distributed processes from start-to- finish. A paperless electronic record keeping system will add significant value to support these goals. LIMS, SDMS, LES and ELN products all reduce variability, transcription errors. Do we believe that traditional paper based systems could ever support these complex processes?